CYTH News and Press, Cyclo Therapeutics Inc. From 02/09/22

Most treatments for Alzheimer's disease either lead to only temporary improvements in cognition or only minimally slow down the progression of the disease because they only inhibit peroxynitrite formation. Anavex 2-73 appears to almost stabilize Alzheimer's disease for long periods of...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

– Company’s pivotal Phase 3 study, TransportNPC™, ongoing with global site activation and patient enrollment underway – Data seen to-date provide support for the capacity of Trappsol ® Cyclo™ to stabilize disease progression with hom...

– Live video webcast presentation on Thursday, January 27 th at 10:00 AM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changin...

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...

– Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 s...

Adicet Bio (NASDAQ:ACET) +46% announces positive interim clinical data from first-ever allogeneic, off-the-shelf, Gamma Delta CAR T investigational cell therapy CF Acquisition (NASDAQ:CFVI) +26% Trump social media SPAC confirms $1B PIPE deal Digital Wor...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

Cassava Sciences may have removed an outlier from a previous trial in order to improve results. The company's drug simufilam is likely a zinc chelator; the removal of zinc has some beneficial effects for Alzheimer's patients in part because it inhibits oxidation and nitration. Dru...

Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharm...